Michael (Buz) Waitzkin JD

Buz Waitzkin

Core Faculty

Michael (Buz) Waitzkin, JD

Focus Areas

LLM, Yale University

JD, Stanford University

After more than 30 years of litigation experience in Washington, DC, Michael “Buz” Waitzkin joined the faculty at Duke University where he teaches courses on science law and policy, ethics, data use and privacy, federal regulation and other issues related to emerging technologies. He is the Deputy Director of the Initiative for Science & Society, Director of Graduate Studies for the Masters in Bioethics & Science Policy, a Core Faculty Member in the Duke Margolis Institute for Health Policy and has appointments as Senior Lecturing Fellow in both the Law School and Science & Society and Adjunct Faculty in the Medical School.

He is a co-founder and member of the board of Orbit Genomics, a start-up company developing and commercializing a genomic diagnostic technology, based on microsatellites, which others have discarded as “junk DNA”.


He practiced law in the District of Columbia for 35 years, where he handled complex commercial and criminal cases in federal and state trial and appellate courts throughout the country. He has extensive experience in advising the biomedical research community on issues relating to legal and regulatory strategy, product acquisition, exclusivity strategies, clinical research and ethics. He also served as Special Counsel to the President in the White House Counsel’s Office.

He attended the University of Virginia (BA 1971; Phi Beta Kappa, Echols Scholar), Stanford Law School (JD 1974) and Yale Law School (LLM 1975, Commonwealth Fellow in Law, Science and Medicine).

Kaye DR, Lee H-J, Gordee A, George DJ, Ubel PA, Scales CD, et al. Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. JCO Oncol Pract. 2023 Apr;19(4):e600–17.

Dzimitrowicz HE, Wilson LE, Jackson BE, Spees LP, Baggett CD, Greiner MA, et al. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO oncology practice. 2023 Feb;19(2):e213–27.

Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, et al. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). Urology. 2022 Oct;168:129–36.